| Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors A Richters, SK Doyle, DB Freeman, C Lee, BS Leifer, S Jagannathan, ... Cell chemical biology 28 (2), 134-147. e14, 2021 | 58 | 2021 |
| Advances in discovering small molecules to probe protein function in a systems context SK Doyle, MS Pop, HL Evans, AN Koehler Current opinion in chemical biology 30, 28-36, 2016 | 23 | 2016 |
| A small-molecule inhibitor to the cytokine interleukin-4 SP Quinnell, BS Leifer, ST Nestor, K Tan, DF Sheehy, L Ceo, SK Doyle, ... ACS Chemical Biology 15 (10), 2649-2654, 2020 | 9 | 2020 |
| Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors JD Seixas, BB Sousa, MC Marques, A Guerreiro, R Traquete, T Rodrigues, ... RSC Chemical Biology 1 (4), 251-262, 2020 | 8 | 2020 |
| Small molecule modulators of the androgen receptor D Freeman, NB Struntz, SK Doyle, A Richters, AN Koehler US Patent 10,961,216, 2021 | 4 | 2021 |
| Rationally designed potent BMX inhibitors reveals mode of covalent binding at the atomic level JD Seixas, BB Sousa, MC Marques, A Guerreiro, R Traquete, T Rodrigues, ... | 3 | 2020 |
| Nailing Down a Notoriously Elusive Cancer Target: Direct Inhibition of MYC by a Covalent Small Molecule MJ Henley, SK Doyle, AN Koehler Cell Chemical Biology 28 (1), 1-3, 2021 | 2 | 2021 |
| An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives BS Leifer, SK Doyle, A Richters, HL Evans, AN Koehler Methods in Enzymology 610, 191-218, 2018 | 2 | 2018 |
| Small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1 AN Koehler, S Doyle, B Leifer, M Henley, BW Schaefer, M Wachtel US Patent 11,964,022, 2024 | | 2024 |
| Small molecule inhibitors of interleukin-4 A Vegas, S Quinnell, D Sheehy, TAN Kelly, CEO Luke, ST Nestor, ... US Patent App. 17/206,542, 2021 | | 2021 |
| Small molecule modulators of the androgen receptor ANK David Freeman, Nicholas B. Struntz, Shelby K. Doyle, Andre Richters | | 2021 |
| Targeting oncogenic transcription in prostate cancer with a novel, oral bioavailable, and ultra-selective CDK9 inhibitor A Richters, D Freeman, C Lee, F Kabinger, S Doyle, B Leifer, P Mikochik, ... Cancer Research 80 (16), 2020 | | 2020 |
| Target engagement approaches to validate small-molecule binders of the pioneering transcription factor FOXA1 HL Evans, SK Doyle, MS Pop, B Leifer, K Ziadkhanpour, AN Koehler Cancer Research 77 (13_Supplement), 5221-5221, 2017 | | 2017 |
Helen Louise EvansPostdoctoral Associate, MITVerified email at mit.edu
